# Pharma Intellectual Property and PQC **Source**: https://quantumsequrity.com/blog/pharma-ip-pqc **Category**: Industry & Use Cases --- [← Back to Blog](../../blog) Industry & Use Cases # Pharma Intellectual Property and PQC 10 min read A new drug application can take twelve to fifteen years and over a billion dollars to bring through clinical trials and FDA review. The intellectual property generated during that process, including molecular structure data, synthesis routes, formulation know-how, manufacturing process parameters, and clinical trial data, is the most valuable single output of the company. Patent protection runs twenty years from filing, but trade secrets such as manufacturing process parameters and bioprocess optimization data have no expiration date and remain commercially relevant indefinitely. When a pharmaceutical company encrypts that data today with RSA-2048 or ECDSA, the cryptographic horizon needs to extend across the patent window and beyond. Quantum computing will eventually break those algorithms, and the commercial value of the underlying data will not have diminished. This article walks through the unique cryptographic posture pharma needs, the FDA submission requirements that intersect with encryption, and how to think about a post-quantum migration that respects the long sensitivity windows of pharmaceutical IP. ## The Pharma IP Sensitivity Horizon A small molecule drug receives twenty years of patent protection from the date of filing, but the effective market exclusivity is typically twelve to fourteen years after FDA approval. Generic competition then erodes pricing rapidly. The window of maximum commercial sensitivity for the underlying chemistry and clinical data is the development period plus the patent life, which can run thirty years from initial discovery to patent expiration. Trade secrets are the longer game. Manufacturing process parameters, cell line characteristics for biologics, fermentation optimization data, and analytical method development records are protected as trade secrets indefinitely. Coca-Cola style protection. The Eli Lilly insulin manufacturing process from the 1920s is still partially trade secret. If a quantum-era adversary decrypts a pharma company's archived process documentation in 2045, the commercial value to a generic manufacturer or a counterfeit operation is enormous. This is the classic harvest now, decrypt later problem at industrial scale. State actors have been documented attempting to exfiltrate pharmaceutical IP for decades. The 2014 Boston Scientific theft case, the 2020 Moderna intrusion attempt, and the broader pattern of nation-state intelligence collection against the biotech sector all point to the same conclusion: encrypted pharma IP is high-value targeting data for a future quantum decryption capability. See [What Is Post-Quantum Cryptography](what-is-post-quantum-cryptography) and [Harvest Now, Decrypt Later](harvest-now-decrypt-later) for the broader threat model. ## FDA Submissions and Electronic Common Technical Document FDA submissions flow through the Electronic Common Technical Document (eCTD) format, the global standard adopted by FDA, EMA, PMDA, and Health Canada for drug applications. eCTD is delivered through the FDA Electronic Submissions Gateway (ESG), which uses S/MIME for message-level signing and TLS for transport. Both layers depend on cryptography that needs to migrate to post-quantum standards. A typical eCTD submission for a new drug application contains chemistry, manufacturing, and controls (CMC) data, nonclinical pharmacology and toxicology, clinical trial reports, statistical analysis plans, and proposed labeling. The submission can be tens of thousands of files totaling many gigabytes. Each file is sensitive throughout the patent life of the drug, and selected files (notably manufacturing process descriptions) are sensitive indefinitely as trade secrets. FDA's IT modernization plans include cryptographic agility as a stated goal, but the timeline for full PQC adoption inside the eCTD ecosystem is not yet public. Sponsor companies should not wait. Internal encryption of submission packages should already be moving to hybrid post-quantum, with the assumption that the FDA-side adoption will follow over the coming years. ## Clinical Trial Data Integrity and Confidentiality Clinical trial data has two cryptographic concerns: integrity and confidentiality. Integrity is paramount because trial data is the basis for FDA approval decisions. Any tampering, even allegations of tampering, can derail an approval. The 21 CFR Part 11 regulation requires electronic records to be authentic, verifiable, and protected against unauthorized changes. Digital signatures are the technical mechanism for satisfying Part 11. Today, those signatures are typically RSA or ECDSA based. Quantum computers will eventually be able to forge those signatures retroactively if the public keys are known. While forging a signature on a historical record may not change the FDA approval decision, it can muddy litigation, regulatory inspections, and the integrity of the public scientific record. The migration to ML-DSA or SLH-DSA signatures preserves long-term integrity of the trial archive. Confidentiality is the other half. Patient-level data is protected under HIPAA and equivalent international regulations. Clinical trial protocols and statistical analysis plans are commercially sensitive during the development period. Adverse event databases are sensitive across the lifetime of the drug. The encryption posture for clinical trial data needs to span the entire window from first patient enrolled to the drug coming off-patent, which can be twenty-five years or more. ## Patent Filing and the Public Disclosure Tension Patents are public documents. The whole point of the patent bargain is that the inventor discloses the invention in exchange for a time-limited monopoly. So why does pharma IP need encryption? The answer is that the most valuable IP often lives outside the patent. The patent claims a class of molecules; the trade secret is which specific molecule in the class is actually being developed and what the manufacturing process looks like. The patent describes a synthesis route; the trade secret is the optimized version of that route that produces commercial yields. The patent covers a formulation; the trade secret is the dissolution profile, the excipient supplier, and the analytical method that proves bioequivalence. All of that lives in lab notebooks, electronic batch records, regulatory submissions, internal scientific reports, and email between research teams and manufacturing. Encryption of that data with cryptography that holds against quantum decryption is the only way to preserve the trade secret asset across the patent window. ## NIST Standards for Pharma Encryption NIST has finalized the post-quantum standards that pharma should adopt. FIPS 203 defines ML-KEM, the lattice-based key encapsulation mechanism. FIPS 204 defines ML-DSA, the lattice-based digital signature. FIPS 205 defines SLH-DSA, the stateless hash-based signature scheme. NIST IR 8547 lays out the deprecation timeline for RSA, ECDSA, and finite-field DH. For pharma submissions and trade secret protection, the recommended posture is hybrid encryption combining a classical algorithm like X25519 with ML-KEM-768 or ML-KEM-1024, plus dual signatures combining Ed25519 with ML-DSA-65 or ML-DSA-87. Hybrid retains backward compatibility while gaining post-quantum protection. ML-DSA-87 with its 4,627 byte signatures is a reasonable choice for high-value submissions because the size cost is paid once and the security margin is largest. SLH-DSA is appropriate where stateless reset is a concern; it has the most conservative security assumptions but produces signatures of 7,856 to 49,856 bytes depending on parameters. See [Hybrid Encryption](hybrid-encryption) and the [NIST FIPS Guide](nist-fips-guide) for more. ## Manufacturing Process and Bioprocess Data Pharmaceutical manufacturing data is among the highest-value IP a company holds. For small molecules, the synthesis route, reaction conditions, purification steps, and analytical methods all matter. For biologics, the cell line, fermentation conditions, downstream processing, and formulation are commercially decisive. The full manufacturing batch record for a commercial product can be hundreds of pages. These documents flow between contract manufacturers (CMOs and CDMOs), regulatory consultants, technology transfer teams, and quality control labs. Each handoff is a cryptographic exposure. A CMO running TLS 1.2 with RSA-2048 today is creating decryption opportunities for a future quantum adversary every time a batch record crosses the wire. Pharma quality agreements with CMOs should include cryptographic commitments and PQC migration roadmaps as part of the standard quality system requirements. ## Pharmacovigilance and Adverse Event Data Post-marketing pharmacovigilance generates another long-tail data archive. Adverse event reports, periodic safety update reports, and risk evaluation and mitigation strategies (REMS) data are sensitive for the life of the drug and beyond. FDA, EMA, and PMDA all maintain databases of adverse events that draw from sponsor submissions. The encryption posture for pharmacovigilance data needs to extend across the marketing authorization period, which for a successful drug is twenty years or more after approval. The data is also patient-identified at the source, which adds a HIPAA layer to the U.S. flows and a GDPR layer to European flows. PQC migration in pharmacovigilance systems is a multi-year program because the systems themselves are highly regulated and validation cycles are long. For a related sector view see [PQC for Healthcare HIPAA](pqc-healthcare-hipaa) and [PQC for Pharmaceuticals Trial Data](pqc-pharmaceuticals-trial-data). ## Building a Pharma PQC Migration Program A practical migration program for a pharma company has three phases. Phase one is inventory: every system that handles regulated data, every TLS terminator, every signing key, every HSM, every contract with a CMO or research partner. The output is a Cryptographic Bill of Materials (CBOM) keyed to the systems and the data classifications. Phase two is pilot. The right pilot for pharma is usually around the FDA submission gateway, a single CMO link, or a clinical trial electronic data capture system. The pilot validates that hybrid PQC works inside the existing TLS infrastructure, that signing throughput is acceptable, and that integrity verification on the receiving side works as designed. Phase three is scale. Move TLS terminators to hybrid PQC across the company. Migrate signing keys for regulatory submissions, internal document signing, and code signing. Update the quality system documentation to reference NIST FIPS 203, 204, and 205. Establish vendor management requirements for PQC commitments from CMOs, CROs, and other partners. The whole program should align with NIST IR 8547 deprecation timelines and reference the joint CISA-NIST-NSA quantum readiness factsheet. Pharma is a regulated industry, and regulators reward documentation of disciplined risk management. Quality system documentation should reference the relevant NIST publications and demonstrate that the cryptographic refresh is part of routine quality management rather than a reactive response to a future incident. ## Computational Drug Discovery and AI Model Confidentiality Modern drug discovery increasingly relies on computational platforms that combine traditional molecular dynamics with machine learning models trained on proprietary data. AlphaFold democratized protein structure prediction, but the proprietary follow-on work at major pharmaceutical companies and biotech startups uses internal model variants trained on internal experimental data. The trained model weights themselves become valuable IP, separate from the underlying compounds and synthesis routes. For PQC, computational drug discovery introduces new cryptographic touchpoints. The training data flows from research labs to ML platforms. The model weights flow from training infrastructure to inference platforms. The inference outputs flow back to research teams as candidate molecules for synthesis and testing. Each of these data flows is sensitive, often for the entire patent life of any compound that emerges from the workflow. Federated learning, where multiple pharma companies pool data without sharing it directly, adds another layer. Federated learning rounds involve cryptographic protocols that combine classical and lattice-based primitives. PQC migration of federated learning is an active research area, with the underlying secure aggregation protocols needing to migrate from classical Diffie-Hellman to ML-KEM. Pharma companies participating in federated learning consortia should include PQC commitments in the participation agreements. The broader trend is that computational drug discovery generates archive data with the same long-tail sensitivity as traditional bench data. The encryption posture must hold across the patent life of every compound the platform contributes to discovering, which often means encrypting today against a quantum threat that materializes decades from now. Pharmaceutical CIOs and Chief Information Security Officers should treat their computational drug discovery platforms as PQC migration priorities alongside the more familiar regulatory submission systems. ## Frequently Asked Questions ### Does the FDA require post-quantum cryptography? Not yet by name. FDA submissions go through the Electronic Submissions Gateway, which uses standard S/MIME and TLS. FDA has stated cryptographic agility as a goal in its IT modernization plans, but specific PQC mandates have not been published. Sponsors should not wait; internal encryption of submission packages should already be moving to hybrid PQC. ### How long does pharma IP need to remain confidential? For patented drugs, the commercial sensitivity window is roughly twenty years from filing, with the most valuable period being the post-approval marketing exclusivity. For trade secrets like manufacturing process parameters, sensitivity is indefinite. Encryption needs to hold across the entire window. ### Are clinical trial signatures vulnerable to quantum forgery? RSA and ECDSA signatures on archived clinical trial records can in principle be forged by a sufficiently capable quantum computer. Migrating to ML-DSA or SLH-DSA preserves long-term integrity of the archive. ### What is the biggest pharma cryptographic exposure today? The flow of manufacturing data and clinical trial data across CMOs, CROs, and regulatory consultants is the highest exposure surface. Contracts should require PQC commitments and migration roadmaps from all third parties. ### Should small biotech companies worry about quantum? Yes. Small biotechs hold the IP that gets acquired or licensed by large pharma. Their cryptographic posture often becomes the larger company's posture by inheritance. State actors target small biotechs precisely because their security investment is typically lower and the IP is concentrated. ### How does PQC interact with FDA Part 11 electronic records? Part 11 requires electronic records to be authentic, verifiable, and protected against unauthorized changes. Digital signatures are the technical mechanism. Migrating from RSA or ECDSA signatures to ML-DSA or SLH-DSA preserves Part 11 compliance while gaining post-quantum protection. The transition needs to be documented in the validated state of the systems involved. ### How does GDPR affect pharma PQC migration in Europe? The European General Data Protection Regulation (GDPR) requires appropriate technical and organizational measures to protect personal data. Patient-identified clinical trial data, pharmacovigilance data, and other personal health data fall under GDPR. The European Data Protection Board has published guidance on encryption as a recommended technical measure. While GDPR does not specifically mandate PQC, the obligation to use "state of the art" measures increasingly aligns with post-quantum cryptography as the threat landscape evolves. Pharma companies subject to GDPR should include PQC migration in their data protection impact assessments. ### What about NIST IR 8214 (threshold cryptography) for pharma signing applications? NIST IR 8214 covers threshold cryptography concepts and standards work. For pharma applications where multiple parties must co-sign regulatory documents (clinical trial principal investigators, study coordinators, statistical reviewers), threshold variants of ML-DSA could provide stronger assurance than single-signer ML-DSA. Threshold ML-DSA is an active research area but not yet standardized. Pharma companies pursuing the highest assurance for regulatory document signing can consider threshold approaches, with the understanding that they currently require non-standardized constructions. ## Sources - FDA. "Electronic Submissions Gateway." fda.gov. - FDA. "21 CFR Part 11: Electronic Records; Electronic Signatures." fda.gov. - NIST. "FIPS 203: Module-Lattice-Based Key-Encapsulation Mechanism." nist.gov. - NIST. "FIPS 204: Module-Lattice-Based Digital Signature." nist.gov. - NIST. "FIPS 205: Stateless Hash-Based Digital Signature." nist.gov. - NIST. "NIST IR 8547: Transition to Post-Quantum Cryptography Standards." nist.gov. - CISA, NIST, NSA. "Quantum-Readiness: Migration to Post-Quantum Cryptography." cisa.gov. - European Data Protection Board. "Guidelines on Personal Data Breach Notification." edpb.europa.eu. ## Related Articles - [What Is Post-Quantum Cryptography](what-is-post-quantum-cryptography) - [Harvest Now, Decrypt Later](harvest-now-decrypt-later) - [PQC for Pharmaceuticals Trial Data](pqc-pharmaceuticals-trial-data) - [PQC for Healthcare HIPAA](pqc-healthcare-hipaa) - [Hybrid Encryption](hybrid-encryption) --- ### Protect Your Data Before Q-Day Arrives QNSQY's NIST-standardized post-quantum encryption protects files against both current and quantum-era threats. [Try QNSQY](../../pricing)